Shire exercises option on adenosine A2A antagonist candidate for CNS
This article was originally published in Scrip
Executive Summary
Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Under the agreement Heptares has granted Shire an exclusive licence to worldwide development and commercial rights to A2A antagonists discovered by Heptares. Heptares receives an upfront option fee and is also eligible to receive milestone payments up to $190 million plus royalties on product sales. Further terms are not being disclosed.